Effect of α-magostin on nitrosamine induced hepatic carcinogenicity in neonatal pups

Aim/Background

Liver is the crucial metabolizing site of the body, which is very commonly prone to damage through various toxicants. Various toxicants such as nitrosamine common ecological carcinogens, frequently present in the baby feeder bottle, rubber products, latex products, and various ranges of cosmetics. In continuation of our ongoing efforts in the discovery of natural product, herein we wish to report a novel natural product (α-magostin) on tissue protection, chronic hepatic inflammation and oxidative stress induced by diethylinitrosamine (DEN).

Methods

The neonatal pups were subjected to induce the hepatocarcinogenesis using the single intraperitoneal injection of DEN (50 µg/g, body weight). The neonatal pups were euthanized at the end of the experiment and the liver sections were morphologically evaluated. Cell proliferation, biomarker of hepatic oxidative stress and proinflammatory cytokines were also scrutinized.

Results

The result clearly showed the protective effect of α-magostin via inhibition/alteration of the oxidative stress, liver and non liver parameters as dose dependently. Also, α-magostin inhibited the progression of the toxic lesion expansion by DEN. α-magostin showed the significant (P < 0.001) inhibition of the inflammation cascade via alteration of the nuclear factor kappa B (NF-κB) signaling pathway may characterize a novel mechanism of action and claim the hepatic tumor inhibitory effect. The histopathology study showed the inflammatory necrosis, normal architecture with small uniform nuclei, normal polyhedral shape hepatocytes, small uniform nuclei of cytoplasm and normal central vein, which was significantly resorted by the α-magostin at dose dependently.

Conclusions

As ac conclusion remarks, we have isolated a novel natural product with potent anti-HCC activity. It was confirmed that the isolated α-magostin have the ability to inhibit the chemically induced HCC and claim a new potent molecules.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.